

**DYRK2 Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP14410b****Specification**

---

**DYRK2 Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [Q92630](#)**DYRK2 Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 8445**Other Names**

Dual specificity tyrosine-phosphorylation-regulated kinase 2, DYRK2

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**DYRK2 Antibody (C-term) Blocking Peptide - Protein Information****Name** DYRK2**Function**

Serine/threonine-protein kinase involved in the regulation of the mitotic cell cycle, cell proliferation, apoptosis, organization of the cytoskeleton and neurite outgrowth. Functions in part via its role in ubiquitin-dependent proteasomal protein degradation. Functions downstream of ATM and phosphorylates p53/TP53 at 'Ser-46', and thereby contributes to the induction of apoptosis in response to DNA damage. Phosphorylates NFATC1, and thereby inhibits its accumulation in the nucleus and its transcription factor activity. Phosphorylates EIF2B5 at 'Ser-544', enabling its subsequent phosphorylation and inhibition by GSK3B. Likewise, phosphorylation of NFATC1, CRMP2/DPYSL2 and CRMP4/DPYSL3 promotes their subsequent phosphorylation by GSK3B. May play a general role in the priming of GSK3 substrates. Inactivates GYS1 by phosphorylation at 'Ser-641', and potentially also a second phosphorylation site, thus regulating glycogen synthesis. Mediates EDVP E3 ligase complex formation and is required for the phosphorylation and subsequent degradation of KATNA1. Phosphorylates TERT at 'Ser-457', promoting TERT ubiquitination by the EDVP complex. Phosphorylates SIAH2, and thereby increases its ubiquitin ligase activity. Promotes the proteasomal degradation of MYC and JUN, and thereby regulates progress through the mitotic cell cycle and cell proliferation. Promotes proteasomal degradation of GLI2 and GLI3, and thereby plays a role in smoothened and sonic hedgehog signaling. Plays a role in cytoskeleton organization and neurite outgrowth via its phosphorylation of DCX and DPYSL2. Phosphorylates CRMP2/DPYSL2, CRMP4/DPYSL3, DCX, EIF2B5, EIF4EBP1, GLI2, GLI3, GYS1, JUN,

MDM2, MYC, NFATC1, p53/TP53, TAU/MAPT and KATNA1. Can phosphorylate histone H1, histone H3 and histone H2B (in vitro). Can phosphorylate CARHSP1 (in vitro).

**Cellular Location**

Cytoplasm. Nucleus. Note=Translocates into the nucleus following DNA damage

**Tissue Location**

Testis, after the onset of spermatogenesis.

**DYRK2 Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**DYRK2 Antibody (C-term) Blocking Peptide - Images****DYRK2 Antibody (C-term) Blocking Peptide - Background**

DYRK2 belongs to a family of protein kinases whose members are presumed to be involved in cellular growth and/or development. The family is defined by structural similarity of their kinase domains and their capability to autophosphorylate on tyrosine residues. DYRK2 has demonstrated tyrosine autophosphorylation and catalyzed phosphorylation of histones H3 and H2B in vitro. Two isoforms of DYRK2 have been isolated. The predominant isoform, isoform 1, lacks a 5' terminal insert.

**DYRK2 Antibody (C-term) Blocking Peptide - References**

Taira, N., et al. J. Biol. Chem. 285(7):4909-4919(2010) Yamashita, S., et al. J. Thorac. Cardiovasc. Surg. 138(6):1303-1308(2009) Yamashita, S., et al. Anticancer Res. 29(7):2753-2757(2009) Maddika, S., et al. Nat. Cell Biol. 11(4):409-419(2009) Taira, N., et al. Mol. Cell 25(5):725-738(2007)